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Aims: The demonstration that endothelin production is upregulated in pulmonary artery hypertension (PAH)
served as the rationale for developing endothelin-receptor antagonists (ERAs) as a treatment for PAH. This
article reviews the primary studies demonstrating efﬁcacy of ERAs in PAH.
Main methods: Multicenter, placebo-controlled trials and open-label extension studies.
Key ﬁndings: Two orally active ERAs are currently approved for the treatment of PAH — the dual receptor an-
tagonist bosentan, and the more selective ETA receptor antagonist ambrisentan-based on multicenter
randomized clinical trials demonstrating efﬁcacy and safety. Long-term experience with both agents sup-
ports maintenance of therapeutic effects in most patients. Adverse effects, including altered liver function
and edema may occur and require careful monitoring.
Signiﬁcance: Despite failure to demonstrate efﬁcacy of ERAs in other cardiopulmonary conditions, ERAs have
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The endothelins are a family of 21-amino acid peptides that play a
key role in the regulation of vascular tone. The ﬁrst member of this
family identiﬁed was endothelin-1 (ET-1), a 2492 Da peptide with po-
tent vasoconstrictor properties, isolated by Yanagisawa et al. (1988).-NC-ND license.Two additional endothelin isopeptides, endothelin-2 (ET-2) and
endothelin-3 (ET-3), were subsequently discovered (Inoue et al.,
1989a). All three of these proteins share a high degree of amino acid ho-
mology. They also bear structural similarity to a family of peptides
labeled sarafotoxins which were isolated from the venom of the snake
Atractaspis engaddensis, suggesting a possible shared evolutionary ori-
gin (Takasaki et al., 1988).
Vascular endothelial cells are the major source of endothelins in
humans. However, genes encoding the endothelin peptides are also
found in a wide range of additional cell types including bronchial
518 L.J. Rubin / Life Sciences 91 (2012) 517–521epithelium, macrophages, cardiac myocytes, glomerular mesangium,
and glial cells, among others (Mattoli et al., 1990; Yu and Davenport,
1995; Ehrenreich et al., 1990; Miyauchi and Masaki, 1999).
The years following the discovery of endothelins saw anexplosion of
basic research into these compounds (Michael and Markewitz, 1996).
This has led clinicians to postulate numerous potential applications to
the manipulation of the endothelin system: including the treatment of
renal diseases, systemic hypertension and cerebral vasospasm
(Michael and Markewitz, 1996; Benigni and Remuzzi, 1999).
It is in the therapy of pulmonary vascular disease, however, that
endothelin biology has, thus far, shown its greatest penetration into
the clinical arena. This article will review the current understanding
of the role of endothelins in the physiology and pathophysiology of
the pulmonary circulation, as well as the clinical experiences gained
from the use of endothelin receptor antagonists in the treatment of
pulmonary arterial hypertension.
Physiology
Although marked structural similarity among the endothelins re-
sults in signiﬁcant areas of overlapping biologic function, these com-
pounds are not as similar as they ﬁrst may appear. The human genes
for ET-1, ET-2 and ET-3 are each located on different chromosomes
(Michael and Markewitz, 1996). Furthermore, the distribution of the
three endothelin proteins throughout different tissues appears to be
quite heterogeneous. Endothelial cells, including those of the pulmo-
nary circulation, predominantly generate ET-1. Kidney cells appear to
express higher levels of ET-2 (Masaki, 1998). ET-3 has been found in
high concentrations in the intestine and brain (Shinmi et al., 1989;
Levin, 1995). Each of these three compounds seems to have a distinct
physiologic role that guides their site(s) of expression. Our under-
standing of these unique yet overlapping roles remains incomplete.
Endothelin-1 production
The human ET-1 gene is located on the telomeric region of chro-
mosome 6p (Michael and Markewitz, 1996). The ET-1 gene in-
cludes ﬁve exons that encode mRNA for a large precursor protein:
preproendothelin-1 (PPET-1).
Unlike some other proteins, ET-1 is not kept in secretory granules
(Nakamura et al., 1990) within cells. The rate-limiting step in the bio-
synthesis of ET-1 occurs at the level of transcription (Yanagisawa et
al., 1988). Many stimuli that regulate ET-1 production have evolved
through direct action upon transcription factors (Abstract ﬁgure). It
appears that vascular endothelial cells are able to rapidly increase or
inhibit ET-1 production to regulate vascular tone (Inoue et al., 1989b).
The majority of ET-1 secreted from cultured endothelial cells occurs
from the abluminal side of the cells towards the adjacent vascular
smooth muscle cells, which contain speciﬁc endothelin receptors
(Yoshimoto et al., 1991). Thus, it is important to note that although cir-
culating ET-1 can be detected in the plasma, and may have important
clinical correlations with pulmonary vascular disease (Table 1), theseTable 1
Conditions associated with pulmonary hypertension in which ET-1 levels are increased.
Idiopathic pulmonary artery hypertension, persistent pulmonary hypertension of
the newborn
CREST syndrome
Eisenmenger syndrome
Mitral stenosis
Congestive heart failure
Chronic obstructive pulmonary disease, interstitial lung disease
High altitude exposure
Obstructive sleep apnea
Pulmonary hypertension after heart surgery (cardiopulmonary bypass)plasma levels may not necessarily reﬂect the paracrine action of ET-1
on adjacent smooth muscle cells.Endothelin receptors
There are two distinct receptors for the endothelin family of pep-
tides, endothelin receptor A (ETA) and endothelin receptor B (ETB).
The endothelin receptors belong to the family of receptors connected
to guanine nucleotide-binding (G) proteins (Takuwa et al., 1990). The
two receptors have unique locations (Benigni, 1995) and binding af-
ﬁnities (Masaki, 1998) for the endothelin peptides. ETA receptors
are expressed on pulmonary vascular smooth muscle cells, and have
high afﬁnity for ET-1 and ET-2, with less afﬁnity for ET-3. ETB recep-
tors are located on both pulmonary vascular endothelial cells and
smooth muscle cells. ETB receptors bind all three endothelin isoforms
with nearly equal afﬁnity.
When activated, the ETA receptor located in the pulmonary vascular
smooth muscle cells mediates vasoconstriction. The mechanism is
thought to occur via G protein induced phospholipase C activation;
1,4,5-inositol triphosphate (IP3) formation; and the consequent release
of Ca2+ from intracellular stores (Takuwa et al., 1990). There is some
evidence that ETA receptor may also increase intracellular calcium by
activating non-selective calcium channels on the surface of the smooth
muscle cell (Iwamuro et al., 1999). The vasoconstriction induced by ETA
has been shown to persist even after ET-1 is removed from the receptor,
likely due to persistently elevated concentrations of intracellular Ca2+
(Clarke et al., 1989).
In addition to its powerful vasoconstricting effects, ET-1 is known to
be a potent mitogen, with the ability to induce cell proliferation in a
number of cell types, including vascular smooth muscle cells (Chua et
al., 1992). It has been shown that the mitogenic actions of ET-1 are me-
diated by both the ETA (Davie et al., 2002) and ETB (Sugawara et al.,
1996) receptors. In the pathogenesis of PAH, ET-1 is thought to both
produce vasoconstriction and stimulate vasoproliferation. In the pul-
monary vasculature, ETB receptors are predominantly expressed on en-
dothelial cells (Sakurai et al., 1990; Hirata et al., 1993). ETB receptors on
endothelial cells mediate vasodilation via increased production of nitric
oxide and prostacyclin (Hirata et al., 1993; De Nucci et al., 1988; Filep et
al., 1991). Nitric oxide and prostacyclin also negatively feedback on
ET-1 activity by inhibition of PPET-1 transcription: In the setting of
PAH, where both endothelial nitric oxide and prostacyclin production
are impaired, the pathogenic properties of overexpressed ET-1 are,
therefore, unopposed by these counter-regulatory molecules. Inﬂam-
mation may also play a pathogenic role in some forms of PAH, and
endothelin may be upregulated in this setting, as well.
ETB receptors contribute to the clearance of circulating ET-1, likely
due to internalization of the ET-1/ETB receptor complex into the cell
after binding (Dupuis et al., 1996b).
It has been observed that the normal human lung removes roughly
50% of circulating ET-1, and that it releases a similar quantity, resulting
in the lack of an arterial-to-venous ET-1 gradient across the pulmonary
vasculature in the normal state (Dupuis et al., 1996a).
There are data suggesting that the ETB receptor does not exclusively
mediate pulmonary vasodilation. Under some circumstances it may ac-
tually contribute to pulmonary vasoconstriction, through a population
of ETB receptors located on vascular smooth muscle cells (Masaki,
1995). The vasoconstrictive actions of ETB receptors may become
more pronounced in the pathologic setting of pulmonary hypertension
(Dupuis et al., 2000) than in the normal pulmonary vasculature. It has
been postulated that this action may result from down-regulation of
ETA receptors in states of pulmonary hypertension, possibly as an adap-
tive response to high levels of circulating ET-1 (Kuc and Davenport,
2000).
The vasoconstrictive actions of the ETB receptor may confer a thera-
peutic advantage to the strategy of dual ETA/ETB receptor blockade over
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hypertension.
Pathophysiology
The endothelins are thought to participate in the pathophysiology of
a spectrum of pulmonary vascular diseases. The extent to which the
endothelin system is involved in each disease affecting the pulmonary
circulation is not completely understood, however similarities in the
pathogenesis of this family of disorders suggest that endothelin biology
has broad applicability. The evidence for the role of the endothelin sys-
tem in the pathophysiology of several individual pulmonary vascular
diseases will be subsequently reviewed.
Idiopathic pulmonary arterial hypertension
Patients with idiopathic pulmonary arterial hypertension (IPAH)
demonstrate higher serum levels of ET-1 and higher arterial-to-venous
ratios of ET-1 than healthy controls (Stewart et al., 1991). This phenome-
non may represent increased production of ET-1 by the lung, reduced
clearance by the lung, or a combination of these processes. Lung speci-
mens from patients with IPAH, when compared to those from patients
without pulmonary hypertension, exhibit increased ET-1 staining of the
muscular pulmonary arteries and increased expression of PPET-1 in the
endothelial cells of the same vessels (Giaid et al., 1993). There is further-
more a correlation between the intensity of staining for ET-1 and the pa-
tients' hemodynamic measurements of pulmonary vascular resistance.
Recent studies have shown increased Endothelin Converting Enzyme-1
(ECE-1) in the pulmonary vascular endothelial cells of IPAH patients
(Giaid, 1998), and increased net pulmonary clearance of ET-1 in patients
with IPAH treated with continuous intravenous epoprostenol (Langleben
et al., 1999).
Other pulmonary vascular diseases
Pulmonary hypertension from chronic hypoxia has been shown in
animal models to be associated with increased ET-1 and ETA expres-
sion (Chen and Oparil, 2000; Chen et al., 1997). In these models, it
is also notable that dual ETA/ETB receptor blockade resulted in amelio-
ration of pulmonary hypertensive changes (Eddahibi et al., 1995). In-
terestingly, rat models have also demonstrated regional differences in
endothelin expression throughout the lung, leading some authors to
suggest that heterogeneity of the endothelin system may help to reg-
ulate local responses to hypoxia in the pulmonary circulation
(Takahashi et al., 2001a, 2001b). Detailed human investigations into
the role of the endothelin system in chronic hypoxemia have not
been reported to date.
Pulmonary hypertension from congenital cardiac disease has been
shown in human investigations to correlate with high levels ETA re-
ceptor density and circulating ET-1, which in some instances de-
creased following surgical correction of the cardiac lesions (Bando
et al., 1997; Ishikawa et al., 1995; Lutz et al., 1999). The development
of hypoxemia in patients with congenital shunts may be an additional
factor which magniﬁes the detrimental effects of ET-1 (Allen et al.,
1993).
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) has been
associated with increased activity of the ET-1 system in both animal
(Kim et al., 2000a, 2000b) and human (Bauer et al., 2002) pathologic
studies. Pulmonary hypertensive changes were attenuated in the
presence of dual ETA/ETB receptor blockade in a canine model of
CTEPH (Kim et al., 2000a). It is known that many patients with CTEPH
have a concomitant small vessel vasculopathy which can limit the
hemodynamic improvement following pulmonary endarterectomy.
These data suggest that endothelin may play a role in this process.
Persistent Pulmonary Hypertension of the Newborn (PPHN) has been
associated with increased ET-1 expression and ETA receptor activity ina number of animal studies, involving several different models of
PPHN (Ivy et al., 1994, 1998; Okazaki et al., 1998; Shima et al., 2000).
Clinical studies of human babies with PPHN (Christou et al., 1997;
Kumar et al., 1996; MacDonald et al., 1999; Rosenberg et al., 1993)
have also revealed elevated levels of circulating ET-1, which appear to
correlate with other markers of disease severity.
Clinical use of endothelin receptor antagonists
There are currently 2 endothelin receptor antagonists commercially
available for the treatment of PAH, ambrisentan, and bosentan. These
agents were approved based on results of 12–16 week randomized,
placebo-controlled trials demonstrating their efﬁcacy in improving ex-
ercise capacity, as measured by the 6‐minute walk test. Long-term,
open label studies have conﬁrmed the beneﬁts of this class of medica-
tion. A third ERA, sitaxsentan, a highly selective ETA‐receptor antago-
nist, was approved for marketing in Europe based on two randomized
trials demonstrating similar effects on 6-minute walk test, hemody-
namics, and quality of life parameters as the other two agents; however,
sitaxsentan was withdrawn from marketing and further development
when several cases of fatal hepatic failure were reported with its use.
Ambrisentan
Ambrisentan is a speciﬁc ETA receptor antagonist approved for
PAH, functional classes II and III at doses of 5 mg or 10 mg once
daily. Following a Phase 2, dosing study showing favorable pulmo-
nary hemodynamic effects (Galie et al., 2005), two randomized con-
trolled trials (ARIES 1 and ARIES 2) of ambrisentan (ARIES 1: 5 mg,
10 mg, placebo; ARIES 2: 2.5 mg, 5 mg, placebo) were performed, en-
rolling a total of 394 patients (Galie et al). Both trials achieved the pri-
mary endpoint of placebo-corrected improvement in 6‐minute walk
distance. In ARIES-2, there was a signiﬁcant improvement in time to
clinical worsening in the treatment group as compared with placebo.
There was a trend towards improvement in time to clinical worsening
in the ARIES-1 study, but it was not statistically signiﬁcant (p=
0.307). World Health Organization (WHO) functional class
improvement was signiﬁcant in ARIES-1 and there was trend towards
improvement in ARIES-2 but did not reach statistical signiﬁcance
(p=0.117). 298 patients were enrolled and followed in the long-term
extension study over 48 weeks. Eighteen patients required additional
therapies (prostanoids or phosphodiesterase type-5 [PDE-5] inhibi-
tors). Of the 280 patients continued on ambrisentan monotherapy, the
improvement in 6-minute walk test (6‐MWT) at 12 weeks was 40 m
and maintained at 39 m. Although there were no patients with eleva-
tions in serum aminotransferases >3 times upper limit of normal
while on ambrisentan, in the trials, long-term follow-up has revealed
cases of transaminase elevations which resolve upon discontinuation
of ambrisentan.
Bosentan
Bosentan is a potent, non-peptide, oral endothelin A and B receptor
antagonists, with higher afﬁnity for the ETA subtype receptor. Bosentan
received Food and Drug Administration (FDA) approval November
2001 for patients with WHO functional class III or IV PAH. The ﬁrst
double-blind, placebo-controlled trial randomized 32 patients with
IPAH (84%) or PAH associated with scleroderma with NYHA class III to
bosentan or placebo for 12 weeks (Channick et al., 2001). The primary
endpoint was the placebo-corrected change in 6‐MWT, with secondary
endpoints including change in pulmonary hemodynamics, WHO
functional class, Borg dyspnea index and clinical worsening. The
placebo-corrected improvement in 6‐MWT was 76 m in favor of the
bosentan group, In addition, pulmonary hemodynamics, especially
cardiac index and pulmonary vascular resistance were favorably
affected by bosentan. There were asymptomatic increases in liver
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baseline without discontinuing or changing the dose.
The larger BREATHE-1 (bosentan randomized trial of endothelin an-
tagonist therapy) trial, which randomized 213 patientswith IPAH (70%)
and pulmonary hypertension associated with connective tissue disease
withWHO functional classes III and IV to placebo or bosentan at 125 mg
or 250 mg twice daily, conﬁrmed the efﬁcacy and safety of bosentan
over 16 weeks (Rubin et al., 2002). At 16 weeks, a placebo-corrected
6MWD improvement of 44 m was noted (pb0.001). There were also
improvements in the Borg dyspnea score and time to clinical worsening
in both bosentan groups. Increases in liver aminotransferases greater
than 8 times upper limit of normal was again noted in the bosentan
group and was dose-dependent with 2 patients in the 125 mg group
and 5 patients in the 250 mg group.
In addition to the above “pivotal” trials of bosentan, a randomized
controlled trial of bosentan in PAH patients less functionally impaired
(WHO class II), the EARLY trial, demonstrated a beneﬁt in reducing
pulmonary vascular resistance and preventing clinical worsening at
6 months. No statistically signiﬁcant effect on 6‐minute walk distance
was seen, although baseline walk distance was greater than 400 m,
conﬁrming that this cohort had better baseline exercise capacity
(Galiè et al., 2008).
Bosentan has also been studied in a controlled fashion in patients
with congenital heart disease (Galiè et al., 2006). The BREATHE 5
study demonstrated that, compared to placebo, bosentan improved
six minute walk distance without worsening hypoxemia.
Long‐term survival data in patients on bosentan, although un-
controlled, has been published. Of the 169 IPAH patients enrolled in
the 2 pivotal trials of bosentan, estimated survival at 1 and 2 years
was 96% and 89% respectively, as compared to the predicted survival
of 69% and 57% (McLaughlin et al., 2005). (based on a validated NIH
equation calculating predicted survival from baseline hemodynamics).
It should be acknowledged that there are no prospective controlled sur-
vival data with the newer agents, given obvious ethical concerns about
such trials in the era of existing therapy.
As noted above, ERAs as a class have a propensity for inducing liver
function abnormalities, with a spectrum of severity ranging from
sitaxsentan as the most frequent and causing the most severe hepatic
dysfunction to ambrisentan causing less severe dysfunction and with
greater infrequency. Current regulatory guidelines mandate monthly
monitoring of liver function in patients receiving bosentan, while this
requirement has been removed for ambrisentan based on a review of
safety data from a large cohort of patients treated for several years.
Nevertheless, periodic monitoring of liver function in patients receiving
ambrisentan is still advised.
Future directions
The next steps in the research of endothelin receptor antagonists
for the therapy of PAH appear to have promise. Questions which
remain to be answered include the role of endothelin receptor anta-
gonists in: (a) long‐term efﬁcacy on morbidity and mortality of ERAs
in combination with other agents (b) upfront combination therapy
strategies, for example with a prostanoid or PDE-5 inhibitor, and
(c) expanded disease indications, such as for CTEPH or ﬁbrotic lung
disease.
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